SLShan Liu

Shan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shan Liu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efsubaglutide Alfa for Weight Management in Adults With Overweight or Obesity: A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial

    by Yuqian Bao, Fei Gao, Yufan Wang, Zhenhua Li, Yi Yang, Zhifeng Cheng, Liming Chen, Jianzhong Xiao, Yan Wang, Bowei Liu, et al.

    Background: Obesity is a chronic disease with substantial morbidity. We aimed to evaluate the efficacy and safety of efsubaglutide alfa, a novel GLP-1 receptor agonist, in adults with overweight or obesity. Methods: This multicentre, randomised, double-blind, placebo-controlled, phase 2b trial at 13 hospitals in China randomly assigned adults with obesity (BMI ≥28 kg/m²) or overweight (BMI 24 to <28 kg/m²) with comorbidities (1:1:1:1:1) to efsubaglutide alfa 5 mg, 10 mg, 20 mg once weekly, 20 mg once every 2 weeks, or matched placebo for 18 weeks. The primary endpoint was percentage change in body weight from baseline to week 18. This trial is registered with ClinicalTrials.gov, number NCT06921486. Findings: 199 participants received study drug (mean age 34·4 years [SD 8·2]; mean BMI 32·9 kg/m² [SD 4·3]). At week 18, least-squares mean percentage weight change was −7·95% (SE 1·01) for 5 mg once weekly, −9·99% (SE 1·02) for 10 mg once weekly, −10·58% (SE 1·13) for 20 mg once weekly, and −9·70% (SE 1·11) for 20 mg once every 2 weeks, compared with −3·61% (SE 1·00) for placebo (estimated treatment differences −6·97 to −4·35 percentage points [95% CIs −9·06 to −2·32]; all p<0·001). Proportions achieving ≥5% weight loss were 73·7–81·6% across active doses versus 26·8% for placebo. Gastrointestinal disorders were the most common adverse events (56·4% [combined active] vs 24·4% [placebo]). Interpretation: Efsubaglutide alfa produced clinically meaningful, dose-dependent weight reduction with a safety profile consistent with other GLP-1 receptor agonists. These findings support progression to phase 3 trials at 10 mg, 20 mg once weekly, and 20 mg once every two weeks.

  • Open Access

    Peptide hormone spexin restores beta cell function and improves glycaemic control in mice via regulation of the sodium–potassium pump

    by Yaojing Jiang, Di Wu, Yunzhi Ni, Ying Liu, Huixia Ren, Shan Liu, Chengfang Pan, Jiarong Dai, Quanya Sun, Anran Ma, et al.

    Aims/hypothesis Clinical studies revealed that serum spexin level is positively associated with beta cell function. However, the role of spexin in beta cells remains unclear. We hypothesise that spexin treatment could influence beta cell function and modulate glucose homeostasis in vivo. Methods We analysed glucose-stimulated insulin secretion (GSIS) and beta cell proliferation in mice and isolated mouse islets. Using mice fed a high-fat diet (HFD) and an HFD/streptozocin (STZ)-induced diabetes mouse model, we investigated the effects of spexin on glucose homeostasis and beta cell function. We performed a pull-down/MS assay and a cell-based binding assay to identify the binding partner of spexin on the beta cell surface. An ion pump activity assay and Atp1a1+/− mice were used to explore the underlying regulatory mechanisms. The effects of spexin on beta cell function were further measured on isolated human islets. Results We observed that spexin treatment increased GSIS in chow-diet-fed mice and isolated mouse islets. Spexin treatment also promoted beta cell proliferation in mouse islets and pancreatectomised mice. Furthermore, spexin treatment improved glucose tolerance in HFD-fed mice and attenuated hyperglycaemia in an HFD/STZ-induced diabetes mouse model, along with an elevated serum insulin level and increased beta cell proliferation. Spexin showed specific binding to the beta cell surface. The pull-down/MS assay demonstrated that spexin bound to the α1 subunit of sodium–potassium ATPase (ATP1A1), resulting in pump activity inhibition and subsequent membrane depolarisation. In Atp1a1+/− mice, which had 50% lower levels of ATP1A1, the effects of spexin on GSIS, beta cell proliferation and hyperglycaemia decreased. Importantly, spexin-treated human islets showed increased GSIS and proliferation. Conclusions/interpretation Our study highlights that spexin is a stimulatory factor for beta cell function and proliferation, and suggests that spexin is a diabetes therapeutic target for beta cell intervention. Graphical Abstract


  • Open Access

    EMC10 modulates hepatic ER stress and steatosis in an isoform-specific manner

    by Kuangyang Chen, Yahao Wang, Jia Yang, Nora Klöting, Chuanfeng Liu, Jiarong Dai, Shuoshuo Jin, Lijiao Chen, Shan Liu, Yuzhao Liu, et al.